Pharmacokinetic-pharmacodynamic study of apomorphine's effect on growth hormone secretion in healthy subjects

Fundamental and Clinical Pharmacology

Volumn 17, Issue 4, 2003, Pages 473-481

  Aymard, Guy ^a   Berlin, Ivan ^a   De Brettes, Benoît ^a   Diquet, Bertrand ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Apomorphine; Growth hormone; Pharmacodynamic; Pharmacokinetics

Indexed keywords

APOMORPHINE; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; GROWTH HORMONE;

ACCURACY; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG HALF LIFE; FEMALE; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE RELEASE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; HYPOTHALAMUS HYPOPHYSIS SYSTEM; HYSTERESIS; MALE; NAUSEA; NORMAL HUMAN; PALLOR; PENIS ERECTION; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SWEATING; VOMITING;

ADULT; APOMORPHINE; AREA UNDER CURVE; CROSS-OVER STUDIES; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALF-LIFE; HUMAN GROWTH HORMONE; HUMANS; MALE; MODELS, BIOLOGICAL;

EID: 0041668153     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1472-8206.2003.00152.x     Document Type: Article

References (44)

1. Jaber M., Robinson S.W., Missale C., Caron M.G. Dopamine receptors and brain function. Neuropharmacology (1996) 35 1503-1519.
2. Fabbrini G., Braun A., Mouradian M.M., Tamminga C.A., Chase T.N. Dopamine D-1 receptor agonist stimulation of prolactin secretion in man. J. Neural. Transm. (1988) 71 159-163.
3. Brambilla F., Bellodi L., Perna G., Arancio C., Bertani A. Dopamine function in obsessive-compulsive disorder: growth hormone response to apomorphine stimulation. Biol. Psychiatry (1997) 42 889-897.
4. Meister B., Hokfelt T., Vale W.W., Goldstein M. Growth hormone releasing factor (GRF) and dopamine coexist in hypothalamic arcuate neurons. Acta Physiol. Scand. (1985) 124 133-136.
5. Seaman P., Van Tol H.H. Dopamine receptor pharmacology. Curr. Opin. Neurol. Neurosurg. (1993) 6 602-608.
6. Ettigi P., Lal S., Martin J.B., Friesen H.G. Effect of sex, oral contraceptives, and glucose loading on apomorphine-induced growth hormone secretion. J. Clin. Endocrinol. Metab. (1975) 40 1094-1008.
7. Lal S., Martin J.B., De la Vega C.E., Friesen H.G. Comparison of the effect of apomorphine and L-DOPA on serum growth hormone levels in normal men. Clin. Endocrinol. (1975) 4 277-285.
8. Balldin J., Alling C., Gottfries C.G., Lindstedt G., Langstrom G. Changes in dopamine receptor sensitivity in humans after heavy alcohol intake. Psychopharmacology (1985) 86 142-146.
9. Balldin J.I., Berggren U.C., Lindstedt G. Neuroendocrine evidence for reduced dopamine receptor sensitivity in alcoholism. Alcohol. Clin. Exp. Res. (1992) 16 71-74.
10. Balldin J., Berggren U., Lindstedt G., Sundkler A. Further neuroendocrine evidence for reduced D2 dopamine receptor function in alcoholism. Drug. Alcohol. Depend. (1993) 32 159-162.
11. Rotrosen J., Angrist B.M., Gershon S., Sachar E.J., Halpern F.S. Dopamine receptor alteration in schizophrenia: neuroendocrine evidence. Psychopharmacology (1976) 51 1-7.
12. Ettigi P., Nair N.P.V., Lal S., Cervantes P., Guyda H. Effect of apomorphine on growth hormone and prolactin secretion in schizophrenic patients, with or without oral dyskinesia, withdrawn from chronic neuroleptic therapy. J. Neurol. Neurosurg. Psychiatry (1976) 39 870-876.
13. Hirschowitz J., Zemlan F.P., Hitzemann R.J., Fleischmann R.L., Garver D.L. Growth hormone response to apomorphine and diagnosis: a comparison of three diagnostic systems. Biol. Psychiatry (1986) 21 445-454.
14. Muller E.E., Parati E.A., Panerai A.E., Cocchi D., Caraceni T. Growth hormone hyperresponsiveness to dopaminergic stimulation in Huntington's chorea. Neuroendocrinology (1979) 28 313-319.
15. Wiesbeck G.A., Mueller T., Wodarz N. et al. Growth hormone response to placebo, apomorphlne and growth hormone releasing hormone in abstinent alcoholics and control subjects. Drug Alcohol Depend. (1998) 52 53-56.
16. Pitchot W., Hansenne M., Gonzalez Moreno A., Ansseau M. Effect of previous antidepressant therapy on the growth hormone response to apomorphine. Neuropsychobiology (1995) 32 19-22.
17. Mellers J.D., Quinn N.P., Ron M.A. Psychotic and depressive symptoms in Parkinson's disease. A study of the growth hormone response to apomorphine. Br. J. Psychiatry (1995) 167 522-526.
18. Müller-Spahn F., Modell S., Ackenheil M., Brachner A., Kurtz G. Elevated response of growth hormone to graded doses of apomorphine in schizophrenic patients. J. Psychiatr. Res. (1998) 32 265-271.
19. Nicolle E., Pollak P., Serre-Debeauvais F. et al. Pharmacokinetics of apomorphine in Parkinsonian patients. Fundam. Clin. Pharmacol. (1993) 7 245-252.
20. Gancher S.T., Woodward W.R., Boucher B., Nutt J.G. Peripheral pharmacokinetics of apomorphine in humans. Ann. Neurol. (1989) 26 232-238.
21. Sam E., Jeanjean A.P., Maloteaux J.M., Verbeke N. Apomorphine pharmacokinetics in Parkinsonism after intranasal and subcutaneous application. Eur. J. Drug. Metab. Pharmacokinet. (1995) 20 27-33.
22. Przedborski S., Levivier M., Raftopoulos C., Naini A.B., Hildebrand J. Peripheral and central pharmacokinetics of apomorphine and its effect on dopamine metabolism in humans. Mov. Disord. (1995) 10 28-36.
23. Hofstee D.J., Neef C., van Laar T., Jansen E.N.H. Pharmacokinetics of apomorphine in Parkinson's disease: plasma and cerebrospinal fluid levels in relation to motor response. Clin. Neuropharmacol. (1994) 17 45-52.
24. Harder S., Baas H., Demisch L., Simon E. Dose response and concentration response relationship of apomorphine in plasma with Parkinson's disease and end-of-dose dikinesia. Int. J. Clin. Pharmacol. Ther. (1998) 36 355-361.
25. Berlin I., de Brettes B., Aymard G., Diquet B., Arnulf I., Puech A. Dopaminergic drug response and the genotype (Taq IA polymorphism) of the dopamine D2 receptor. Int. J. Neuropsychopharmacol. (2000) 3 35-43.
26. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edn. American Psychiatric Association, Washington, DC, 1994.
27. Sam E., Augustijns P., Verbeke N. Stability of apomorphine in plasma and its determination by high-performance liquid chromatography with electrochemical detection. J. Chromatogr. B (1994) 658 311-317.
28. Bland J.M., Altman D.G. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet (1986) 8 307-310.
29. Bredberg E., Paalzow L.K. Effects of apomorphine on heart rate during simultaneous administration of sulpiride: a challenge of the composed concentration-effect model. J. Pharmacol. Exp. Ther. (1991) 258 1055-1060.
30. Higashi S., Fujita M., Nishimoto Y., Kuroda K., Asaba H., Sakai T. Neuroendocrine studies in dementia patients: responses of plasma GH and PRL following bromocriptine administration. Acta Neurol. Scand. (1994) 90 39-44.
31. Meltzer H.Y., Kolakowska T., Robertson A., Tricou B.J. Effect of low-dose bromocriptine in treatement of psychosis: the dopamine autoreceptor-stimulation strategy. Psychopharmacology (1983) 81 37-41.
32. Nair N.P., Lal S., Iskandar H.I., Etienne P., Wood P.L., Guyda H. Effect of sulpiride, an atypical neuroleptic, on apomorphine-induced growth hormone secretion. Brain Res. Bull. (1982) 8 587-591.
33. 3 dopamine receptors in human striatum. Prog. Neuropsychopharmacol. Biol. Psychiatry (1995) 19 1147-1154.
34. Titeler M., Tedesco J.L., Seeman P. Selective labeling of pre-synaptic receptors by 3H-dopamine, 3H-apomorphine and 3H-clonidine; labeling of post-synaptic sites by 3H-neuroleptics. Life Sci. (1978) 14 587-591.
35. Skirboll L.R., Grace A.A., Bunney B.S. Dopamine auto- and postsynaptic receptors: electrophysiological evidence for differential sensitivity to dopamine agonists. Science (1979) 206 80-82.
36. 3 dopamine receptor antagonist activity and limbic selectivity. J. Pharmacol. Exp. Ther. (1997) 280 73-82.
37. Irifune M., Nomoto M., Fukuda T. Effects of GBR 12909 on locomotor activity and dopamine turnover in mice: comparison with apomorphine. Eur. J. Pharmacol. (1995) 272 79-85.
38. Wiedemann K., Kellner M. Endocrine characterization of the new dopamine autoreceptor agonist roxindole. Exp. Clin. Endocrinol. (1994) 102 284-288.
39. 2-like receptors by amisulpiride: effects on hormone secretion in healthy volunteers. J. Psychiat. Res. (1994) 28 461-473.
40. Eddy R.L., Gilliland P.F., Ibarra J.D., McMurry J.F., Thompson J.Q. Human growth hormone release: comparison of provocative test procedures. Am. J. Med. (1974) 56 179-185.
41. Rahim A., Toogood A.A., Shalet S.M. The assessment of growth hormone in normal young adult using a variety of provocative agents. Clin. Endocrinol. (1996) 45 557-562.
42. Shalet S.M., Toogood A., Rahim A., Brennan B.M. The diagnosis of growth hormone deficiency in children and adults. Endocr. Rev. (1998) 19 203-223.
43. Aimaretti G., Baffoni C., DiVito L. et al. Comparisons among old and new provocative tests of GH secretion in 178 normal adults. Eur. J. Endocrinol. (2000) 142 347-352.
44. Pellini C., De Angelis R., di Natale B., Lukezic M., Mora S., Chiumello G. Dexamethasone in the diagnostic work-up of growth hormone deficiency. Clin. Endocrinol. (1998) 48 223-228.